Phreesia, Inc. (NYSE:PHR) Short Interest Down 30.2% in December

Phreesia, Inc. (NYSE:PHR) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 2,427,866 shares, a decrease of 30.2% from the November 30th total of 3,479,944 shares. Approximately 4.3% of the company’s shares are short sold. Based on an average daily volume of 2,620,410 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 2,620,410 shares, the short-interest ratio is currently 0.9 days. Approximately 4.3% of the company’s shares are short sold.

Phreesia Stock Performance

Shares of PHR traded down $0.03 during midday trading on Monday, reaching $16.99. 910,901 shares of the stock were exchanged, compared to its average volume of 1,866,219. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia has a 52 week low of $15.41 and a 52 week high of $32.76. The company’s 50 day moving average is $20.19 and its two-hundred day moving average is $24.35.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business had revenue of $120.33 million for the quarter, compared to analysts’ expectations of $119.98 million. During the same quarter last year, the firm earned ($0.25) EPS. The business’s revenue for the quarter was up 12.7% on a year-over-year basis. As a group, sell-side analysts expect that Phreesia will post -1.1 EPS for the current year.

Insider Transactions at Phreesia

In other Phreesia news, insider Evan Roberts sold 1,888 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $42,215.68. Following the completion of the transaction, the insider directly owned 724,949 shares in the company, valued at approximately $16,209,859.64. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,241 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $27,748.76. Following the completion of the transaction, the general counsel owned 135,737 shares of the company’s stock, valued at approximately $3,035,079.32. The trade was a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 7,534 shares of company stock worth $165,514. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Phreesia

Several large investors have recently made changes to their positions in PHR. Raymond James Financial Inc. grew its position in Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after buying an additional 375 shares during the period. Diversified Trust Co raised its stake in shares of Phreesia by 1.0% during the 2nd quarter. Diversified Trust Co now owns 45,042 shares of the company’s stock worth $1,282,000 after buying an additional 426 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Phreesia by 2.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock valued at $569,000 after buying an additional 540 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in Phreesia by 9.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company’s stock valued at $251,000 after acquiring an additional 792 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Phreesia by 1.3% in the 3rd quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock worth $1,475,000 after acquiring an additional 812 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PHR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 9th. Piper Sandler upped their price objective on Phreesia from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Friday, September 5th. Mizuho lowered their target price on Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research report on Wednesday, December 10th. Stephens restated an “overweight” rating and issued a $32.00 price target on shares of Phreesia in a research report on Wednesday, September 3rd. Finally, Zacks Research upgraded shares of Phreesia from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.